Profound Medical Corp.
NASDAQ•PROF
CEO: Dr. Arun Swarup Menawat MBA, Ph.D.
セクター: Healthcare
業種: Medical - Devices
上場日: 2019-10-29
Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum. The company also offers Sonalleve, which combines real-time MRI and thermometry for the treatment of uterine fibroids, adenomyotic tissue, palliative pain treatment of bone metastases, osteoid osteoma, and management of benign tumors. Profound Medical Corp. is headquartered in Mississauga, Canada.
連絡先情報
時価総額
$177.02M
PER (TTM)
-3.9
26.5
配当利回り
--
52週高値
$8.95
52週安値
$3.76
52週レンジ
順位60Top 89.2%
2.1
F-Score
改良版 Piotroski 分析
10年ファンダメンタル
弱い • 2.1 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2016-2025
財務ダッシュボード
Q4 2025 データ
売上高
$6.04M+0.00%
直近4四半期の推移
EPS
-$0.37+0.00%
直近4四半期の推移
フリーCF
-$6.57M+0.00%
直近4四半期の推移
2025 Annual 決算ハイライト
主なハイライト
Revenue Growth Strong Revenue reached $16.10M USD in 2025, showing 51% growth from $10.68M USD in 2024, driven by recurring sales.
Gross Margin Expansion Gross margin improved to 71% USD in 2025, up from 66% USD in 2024, reflecting better pricing and sales mix.
Successful Capital Raising Secured $40.80M USD net proceeds from December 2025 offerings to fund US commercialization efforts globally.
Cash Position Maintained Ended 2025 with $59.72M USD cash, supported by recent financing activities, ensuring runway for operations.
リスク要因
Operating Losses Persist Recorded net loss of $42.57M USD in 2025, continuing history of operating losses since inception.
Capital Intensive Business Business requires substantial capital investment for sales expansion and R&D; future financing availability is uncertain.
Market Acceptance Uncertainty Commercial success depends on achieving expected levels of market acceptance for TULSA-PRO system adoption.
Regulatory and IP Challenges Faces risks from complex government regulation, potential IP infringement claims, and evolving compliance requirements globally.
見通し
Focus on US Commercialization Primary focus remains on expanding TULSA-PRO utilization in the US market through direct sales teams.
Continued R&D Investment Plan to continue product research, development, and clinical studies to support future regulatory approvals internationally.
Strategic Partner Expansion Collaborating with partners like Siemens Healthineers to offer complete MRI-guided prostate therapy solutions.
同業比較
売上高 (TTM)
$149.16M
$105.66M
$95.11M
粗利益率 (最新四半期)
92.4%
87.3%
86.7%
主要指標
銘柄コード | 時価総額 | PER (TTM) | ROE (TTM) | 負債比率 |
|---|---|---|---|---|
| CATX | $367.90M | -3.5 | -41.3% | 0.6% |
| ARMP | $349.87M | -7.4 | 70.3% | 198.5% |
| FBRX | $331.21M | -9.1 | -75.6% | 0.0% |
長期トレンド
直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
32.1%
高成長
4四半期純利益CAGR
N/M
収益構造の変化
キャッシュフロー安定性
0%
キャッシュフローに注意が必要
深度リサーチ
次回決算:2026年5月6日
EPS:-
|売上高:-
財務データ
決算説明会
財務レポート
ニュース
損益計算書
バランスシート
キャッシュフロー計算書
財務比率
変化率
損益計算書 | 直近12ヶ月 |
|---|
データなし